Glucagon-related peptides from phylogenetically ancient fish reveal new
approaches to the development of dual GCGR and GLP1R agonists for Type 2
diabetes therapy
Galyna V. Graham, J. Michael Conlon*, Yasser H. Abdel-Wahab, Peter R. Flatt
Diabetes Research Group, School of Biomedical Sciences, Ulster University, Cromore
Road, Coleraine, Northern Ireland BT52 1SA, UK
*Corresponding author:
Prof. J. M. Conlon
School of Biomedical Sciences
Ulster University,
Cromore Road,
Coleraine,
Northern Ireland BT52 1SA, UK
E-mail: [email protected]
Short title: Dual agonist glucagon-related peptides
Key words: insulinotropic; antidiabetic; glucagon, GLP-1, oxyntomodulin, exendin-4,
paddlefish
1
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
Abstract
The insulinotropic and antihyperglycaemic properties of glucagons from the sea
lamprey (Petromyzontiformes), paddlefish (Acipenseriformes) and trout (Teleostei) and
oxyntomodulin from dogfish (Elasmobranchii) and ratfish (Holocephali) are compared
with those of human glucagon and GLP-1 in mammalian test systems. All fish peptides
produced concentration-dependent stimulation of insulin release from BRIN-BD11 rat
and 1.1 B4 human clonal β-cells and isolated mouse islets. Paddlefish glucagon was the
most potent and effective peptide. The insulinotropic activity of paddlefish glucagon
was significantly (P < 0.01) decreased after incubating BRIN-BD11 cells with the
GLP1R antagonist, exendin-4(9-39) and the GCGR antagonist [des-His1,Pro4 ,Glu9]
glucagon amide but GIPR antagonist, GIP(6-30)Cex-K40[Pal] was without effect.
Paddlefish and lamprey glucagons and dogfish oxyntomodulin (10 nmol/L) produced
significant (P < 0.01) increases in cAMP concentration in Chinese hamster lung (CHL)
cells transfected with GLP1R and human embryonic kidney (HEK293) cells transfected
with GCGR. The insulinotropic activity of paddlefish glucagon was attenuated in
CRISPR/Cas9-engineered GLP1R knock-out INS-1 cells but not in GIPR knock-out
cells. Intraperitoneal administration of all fish peptides, except ratfish oxyntomodulin,
to mice together with a glucose load produced significant (P < 0.05) decreases in
plasma glucose concentrations and paddlefish glucagon produced a greater release of
insulin compared with GLP-1. Paddlefish glucagon shares the sequences Glu15-Glu16
and Glu24-Trp25-Leu26-Lys27-Asn28-Gly29 with the potent GLP1R agonist, exendin-4 so
may be regarded as a naturally occurring, dual-agonist hybrid peptide that may serve as
a template design of new drugs for type 2 diabetes therapy.
2
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
1. Introduction
Patients with obesity-related diseases such as Type 2 diabetes mellitus (T2DM) often
cannot be treated effectively with a single pharmaceutical agent [1]. The therapeutic
potential of unimolecular dual- and triple-agonist peptides based upon the primary
structures of the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-
dependent insulinotropic peptide (GIP) together with glucagon is becoming
increasingly apparent. Multi-agonist peptides that target (A) the GLP-1 receptor
(GLP1R) and the glucagon receptor (GCRG), (B) the GLP1R and the GIP receptor
(GIPR), and (C) the GLP1R, GCGR, and GIPR are currently in development [2,3].
Similarly, an enzymatically stable GIP/xenin hybrid peptide has been shown to enhance
β-cell function and improves glucose homeostasis in mice that have been rendered
insulin resistant and glucose intolerant by being fed a high fat diet [4]. A major
advantage of administration of these multi-agonist peptides over their constituent
monotherapies is their improved actions on blood glucose control, appetite,
suppression, weight loss and hyperlipidemia/hypercholesterolemia although some
patients have exhibited adverse effects including diarrhoea, nausea and decreased
appetite [3,5].
An alternative strategy to the use of synthetic hybrid peptides is to exploit the
potential of naturally occurring dual agonist peptides. Oxyntomodulin is a C-terminally
extended form of glucagon that was first identified as an impurity in a commercially
available preparation of bovine/porcine glucagon [6] and is released from L-cells in the
intestine in response to nutrients [7]. A specific receptor for oxyntomodulin has not
been identified but the peptide will activate both the GCGR and the GLP1R, although
with an affinity that is appreciably less than glucagon and GLP-1 respectively.
3
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
Consequently, the peptide will stimulate insulin release and improve glucose tolerance
when administered to mice [8,9]. Oxyntomodulin has received particular attention
because of its ability at pharmacological doses to inhibit appetite and food intake [10].
A GIP-oxyntomodulin hybrid peptide acting through GIP, glucagon and GLP-1
receptors exhibits promising weight reducing and anti-diabetic properties during long-
term administration to high fat fed mice [11]. Recently it has been shown that glucagon
from the European common dogfish Scyliorhinus canicula (Elasmobranchii) [12] acts
as a dual agonist at the glucagon and GLP-1 receptors and peptidase-resistant analogs
showed potent insulin releasing activity in vitro and antihyperglycaemic activity in
mice [13,14]. Similarly, the insulinotropic and glucose-lowering actions of zebrafish
GIP in mice involve interaction with both the GLP-1 and GIP receptors [15].
Glucagon has been isolated from the principal islets (Brockmann bodies) of a
wide range of teleost species and the genes encoding proglucagon in several teleosts
have been characterized (reviewed in [16]). The peptide has also been purified from
several phylogenetically more ancient fishes. Glucagon has been isolated from the islet
organ of the lampreys Petromyzon marinus, Lampetra fluviatilis, and Geotria australis
(Petromyzontiformes) [reviewed in (17)], from the pancreas of the ray Torpedo
marmorata (Elasmobranchii), and from the pancreata of several primitive
Actinopterygian (ray-finned) fish: the N. American paddlefish Polyodon spathula
(Polyodontidae) and the sturgeons Huso dauricus and Scaphirhynchus albus
(Acipenseriformes), the bichir Polypterus senegalis (Polypteriformes), the alligator gar
Lepisosteus spatula (Lepisosteiformes), and the bowfin Amia calva (Amiiformes)
(reviewed in [18]). Components comprising glucagon extended from its COOH-
terminal region by additional amino acid residues that may represent orthologs of
mammalian oxyntomodulin have been purified from the pancreata of S. canicula and
4
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
the Pacific ratfish Hydrolagus colliei (Holocephali) [12,19]. It is estimated that the
Petromyzontiformes diverged from the line of evolution leading to mammals between
500 and 550 million years ago (MYA) and the Elasmobranchii diverged around 420
MYA. The divergence of the Holocephali and the Elasmobranchii is also ancient (410
MYA) and the Polyodontidae are believed to have diverged from the Acipenseriformes
approximately 180 MYA [20].
The biological activities and physiological roles of the proglucagon-derived
peptides have not been investigated the ancient fishes but, in teleosts, the
responsiveness of hepatocytes to glucagon is limited to high concentrations while
physiological concentrations of GLP-1 effectively regulate hepatic metabolism by
stimulating gluconeogenesis and glycogenolysis. In contrast to mammals, GLP-1 shows
very weak insulinotropic activity in teleosts [21]. In the light of the promising anti-
diabetic effects of dogfish glucagon [13,14], the aim of the present study was to
compare the insulinotropic and antihyperglycemic properties of synthetic replicates of
glucagons from the sea lamprey [22], paddlefish [23], and rainbow trout Onchorynchus
mykiss [24] and oxyntomodulins from dogfish [12] and ratfish [19] with human
glucagon and GLP-1. Effects in vitro were determined using wild-type and genetically
engineered established insulin-producing cell lines and isolated mouse islets. Their
glucose-lowering and insulin stimulating actions in vivo were assessed following acute
administration to NIH Swiss mice together with a glucose load. The primary structures
and molecular masses of the peptides used in this study are shown in Table 1.
2. Materials and methods
2.1. Peptides
5
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
All peptides were supplied in crude form by EZBiolab Inc. (Carmel, IN, USA). The
peptides were purified to > 98% homogeneity by reversed-phase HPLC on a (2.2 cm x
25 cm) Vydac 218TP1022 (C-18) column (Grace, Deerfield, IL, USA). The
concentration of acetonitrile in the eluting solvent was raised from 21% to 56 % over
60 min using a linear gradient. Absorbance was measured at 214 nm and the flow rate
was 6 ml/min. The identities of the peptides were confirmed by matrix-assisted laser
desorption ionization time-of-flight mass (MALDI-TOF) spectrometry using a Voyager
DE PRO instrument (Applied Biosystems, Foster City, USA) as previously described
[25].
2.2. In vitro insulin release studies using BRIN-BD11 and 1.1B4 cells
The abilities of the purified synthetic peptides (0.01 nmol L-1 - 3 µmol L-1; n = 8) to
stimulate the rate of release of insulin from BRIN-BD11 rat clonal β-cells [26] and
1.1B4 human-derived pancreatic β-cells [27] was determined as previously described
[28] In a second series of experiments, the effects of 1 µmol L-1 concentrations of the
(A) GLP-1 receptor antagonist, exendin-4(9-39) [29], (B) glucagon receptor antagonist,
[desHis1,Pro4,Glu9]glucagon amide [30], and (C) glucose-dependent insulinotropic
peptide (GIP) receptor antagonist, GIP(6-30)Cex-K40[palmitate] [31] on the insulin-
releasing activity of the peptides (0.1 µmol/L) were studied by incubating BRIN-BD11
cells for 20 min at 37 ˚C in Krebs-Ringer Bicarbonate (KRB) buffer, pH 7.4
supplemented with 5.6 mmol L-1 glucose as previously described [15]. All samples
were stored at −20 °C prior to measurement of insulin release by radioimmunoassay
[29].
6
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
2.3. Insulin release studies using isolated mouse islets
Collagenase-isolated pancreatic islets from adult, male National Institutes of Health
(NIH) Swiss mice (Harlan Ltd, Bicester, UK) [30] were cultured for 48 h at 37 °C in an
atmosphere of 5% CO2 and 95% air as previously described [15, 28] The islets were
incubated with peptides (10 nmol L-1 and 1 µmol L-1; n =4) and alanine (10 mmol L-1; n
= 4)) for 1 h at 37˚C in KRB buffer supplemented with 16.7 mmol L-1 glucose. Insulin
release was measured by radioimmunoassay and the insulin content was measured by
extraction with acid-ethanol as previously described [28].
2.4 Effects on cAMP production
CHL Chinese hamster lung cells transfected with the human GLP-1 receptor (GLP1R)
[29] and HEK293 human embryonic kidney cells transfected with the human
glucagon receptor (GCGR) [34] were cultured, seeded, and incubated with KRB
buffer containing 0.1% (w/v) bovine serum albumin, 5.6 mmol L-1 glucose, 200 μmol
L-1 3-isobutyl-1-methylxanthine (IBMX) and test peptides (10 nmol L-1 and 1 µmol L-1)
as previously described [15] After 20 min, the medium was removed and cells were
lysed before measurement of cAMP using a Parameter cAMP assay kit (R&D Systems,
Abingdon, UK) according to the manufacturer’s recommended protocol.
2.5. Insulin release studies using CRISPR/Cas9-engineered INS-1 cells
Wild-type INS-1 832/3 rat clonal pancreatic β-cells and CRISPR/Cas9-engineered cells
with knock-out of either the GLP-1 receptor (GLP1R KO) or the GIP receptor (GIPR
7
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
KO) [35] were cultured as described for BRIN-BD11 cells but with the addition of
1 mmol L-1 sodium pyruvate and 50 mmol L-1 2-mercaptoethanol to the medium [15].
The cells were incubated with 10 nmol L-1 and 1 μmol L-1 concentrations of GLP-1,
glucagon, GIP, and fish peptides for 20 min 37 °C in KRB buffer supplemented with
5.6 mmol L-1 glucose and insulin release was measured by radioimmunoassay.
2.6. In vivo insulin release studies
All experiments involving animals were performed in accordance with the UK Animals
(Scientific Procedures) Act 1986, EU Directive 2010/63EU, the European Convention
for the Protection of Vertebrate Animals used for Experimental and other Scientific
Purposes' (Council of Europe No 123, Strasbourg 1985 and approved by Ulster
University Animal Ethics Review Committee. Acute in vivo studies were carried out
using 8-10 week-old male National Institutes of Health (NIH) Swiss mice (n = 6)
maintained in an environmentally controlled room (12 h:12 h light/darkness cycle, 22 ±
2 oC) with free access to a standard rodent diet and water. Peptides were dissolved in
0.9 % NaCl-water and stored as a 1 mmol L-1 stock solution. After an overnight fast,
glucose (18 mmol kg body weight-1), either alone or together with peptide (25 nmol kg
body weight-1), was administrated intraperitoneally in a volume of 100 µL to the mice
as previously described [28]. Blood samples (approx. 60 µL) were collected from a tail
vein at the time points shown in Fig. 7. The animals receiving peptides did not exhibit
any behavioural differences from control animals when monitored over a 24 h period.
8
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
2.7. Statistical analysis
Results were analysed in GraphPad PRISM (Version 5.0) and presented as mean ±
SEM. Statistical analyses were carried out by unpaired Student's t test (non-parametric,
with two-tailed P values and 95% confidence interval) and by one way ANOVA with
Bonferroni post-hoc test wherever applicable. Results were considered significant if P <
0.05. Area under the curve (AUC) analysis was performed using the trapezoidal rule
with baseline correction.
3. Results
3.1. In vitro insulin-releasing activity
The rate of insulin release from BRIN-BD11 rat clonal β-cells in the presence of 5.6
mmol L-1 glucose alone was 1.02 ± 0.02 ng 106 cells-1 20 min-1. The effects of
incubation with increasing concentrations of the fish glucagon-related peptides, human
glucagon, and human GLP-1 on insulin release are shown in Fig. 1. All peptides
produced significant and concentration-dependent increases the rate of insulin release
compared with the rate in the presence of 5.6 mmol L-1 glucose alone. As shown in
Table 2, the most potent peptide was paddlefish glucagon which produced a significant
stimulation of insulin release (P < 0.05) from BRIN-BD11 cells at a threshold
concentration of 30 pmol L-1 compared with 10 pmol L-1 for human GLP-1 and 10 nmol
L-1 for human glucagon. Paddlefish glucagon was the most effective peptide producing
a response at 3 µmol L-1 concentrations that was not significantly different from that of
GLP-1 (Table 2).
The rate of insulin release from 1.1B4 human clonal β-cells in the presence of
16.7 mmol L-1 glucose alone was 0.08 ± 0.01 ng 106cells-1 20 min-1. Incubation with all
9
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
fish peptides significantly (P < 0.001) stimulated insulin release at concentrations of 1
µmol L-1 compared with the rate in the presence of 16.7 mmol L-1 glucose alone (Fig.
2). Only paddlefish glucagon (P < 0.001) and dogfish oxyntomodulin (P < 0.05)
produced a significant increase at 10 nmol L-1. The rates of insulin release elicited by 1
µmol L-1 concentrations of glucagons from lamprey and paddlefish and by dogfish
oxyntomodulin were not significantly different to that produced by human GLP-1.
The rate of insulin release from mouse islets incubated for 60 min with 16.7
mmol L-1 glucose was 9.7 ± 1.3 % of the total insulin content. Incubation with all
peptides, except human and trout glucagon, at 1µM concentrations significantly
increased the rate of insulin release compared with the rate with 16.7 mmol L-1 glucose
alone (Fig. 3). Lamprey glucagon and dogfish oxyntomodulin were also effective at 10
nmol L-1. The stimulatory effects of 1 µmol L-1 concentrations of glucagons from
lamprey and paddlefish and dogfish oxyntomodulin on insulin release were not
significantly different from the effect produced by 1 µmol L-1 GLP-1.
3.2. Receptor antagonist studies
The in vitro insulinotropic activities of all peptides, except trout and human glucagons
and GIP, were significantly decreased when BRIN-BD11 cells were co-incubated with
the GLP-1 receptor antagonist, exendin-4(9-39) (Fig. 4A). Co-incubation with the
glucagon receptor antagonist [des-His1,Pro4,Glu9]glucagon amide significantly
attenuated the action of all peptides except ratfish oxyntomodulin, GLP-1 and GIP
(Fig. 4B). Human GIP was the only peptide whose stimulatory effect on insulin release
was attenuated by the GIP receptor antagonist, GIP(6-30)Cex-K40[palmitate] (Fig. 4C).
10
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
3.3. Effects on cAMP production
At the high concentration of 1 µmol L-1, all peptides except trout glucagon and GIP
significantly stimulated cAMP production in CHL cells transfected with the human
GLP-1 receptor (GLP1R) [29] (Fig. 5A). However, at a concentation of 10 nmol L-1
only incubations with lamprey and paddlefish glucagons, dogfish oxyntomodulin, and
GLP-1 produced significant (P < 0.001) increases in cAMP production. Similarly, at 1
µmol L-1 concentration significant stimulation of cAMP production in HEK293 cells
transfected with the human glucagon receptor (CGCR) [34] was observed after
incubating the cells with all peptides, except ratfish oxyntomodulin and GIP (Fig. 5B).
At the lower concentration of 10 nmol L-1, only lamprey and paddlefish glucagons and
dogfish oxyntomodulin among the fish peptides significantly (P < 0.05) stimulated the
activation of adenylate cyclase.
3.4. Insulin releasing activities using CRISPR/Cas9-engineered INS-1 cells
Incubation of wild type INS-1 cells with glucagon, GLP-1, GIP, and all fish peptides
(10 nmol L-1 and 1 μmol L-1) significantly increased the rate of insulin release
compared with the rate in the presence of 5.6 mmol L-1 glucose alone (Fig. 6A). The
stimulatory effect on insulin release in response to incubations with lamprey glucagon,
dogfish oxyntomodulin, and GLP-1 (10 nmol L-1 and 1 µmol L-1) was abolished in the
GLP-1 KO cells and the responses to paddlefish glucagon and ratfish oxyntomodulin
were significantly attenuated compared with the effects in wild-type INS-1 cells (Fig.
6B). In contrast, the insulin release from GIP KO cells was significantly less that from
the wild-type INS-1 cells only in the case of incubations with 10 nmol/L and 1 μmol/L
11
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
human GIP (Fig. 6C).
3.5. In vivo insulin release studies
Blood glucose concentrations of overnight fasted NIH Swiss mice were significantly
lowered at time points 15, 30 and 60 min after receiving intraperitoneal administration
of glucose (18 mmol kg body weight-1) along with 25 nmol kg body weight-1 of lamprey
glucagon, dogfish oxyntomodulin, and paddlefish glucagon (Fig. 7A) and trout
glucagon (Fig. 7C) compared with animals receiving glucose only. The integrated
responses to the lamprey, dogfish, and paddlefish peptides were not significantly
different from the response to GLP-1 (Fig. 7E). Concomitant with the lower blood
glucose levels, the concentrations of plasma insulin were significantly greater 15 and 30
min after administration of lamprey glucagon, dogfish oxyntomodulin, and paddlefish
glucagon (Fig. 7B), and trout glucagon (Fig 7D) compared with animals receiving
glucose only. The integrated insulin response to paddlefish glucagon was significantly
greater than the response to human GLP-1 (Fig. 7F).
4. Discussion
This study has extended earlier work with dogfish glucagon [13,14] to show that in
mammalian test systems the insulinotropic actions of glucagons from the sea lamprey
and paddlefish and oxyntomodulin from the dogfish are mediated through activation of
both the glucagon and the GLP-1 receptors. In contrast, the effect of ratfish
oxyntomodulin is mediated predominantly, if not exclusively, through interaction with
the GLP-1 receptor and the effect of trout glucagon through interaction with the
glucagon receptor. No activation of the GIPR receptor by any fish peptide studied was
indicated. These conclusions are supported by consistent data involving the use of
12
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15161718
19
20
21
22
23
24
25
26
specific receptor antagonists (Fig. 4), cells transfected with GLP1R and GCGR (Fig. 5),
and CRISPR/Cas9-engineered GLP1R knock-out and GIPR knock-out cells (Fig. 6).
Paddlefish glucagon was the most effective peptide producing a near-maximal increase
in the rate of release of insulin from BRIN-BD11 rat clonal β-cells at a concentration of
3 µmol/L that was not significantly different from that produced by human GLP-1
(Table 2). Along with dogfish oxyntomodulin, paddlefish glucagon produced the
greatest responses in 1.1B4 human clonal β-cells (Fig. 2) and, along with lamprey
glucagon, in isolated mouse islets (Fig. 3). When administered intraperitoneally to
overnight-fasted mice together with a glucose load, glucagons from lamprey and
paddlefish and oxyntomodulin from dogfish were equally effective as human GLP-1 in
lowering blood glucose concentrations and paddlefish glucagon produced a
significantly greater insulin response than an equivalent dose of GLP-1 (Fig. 7).
In an extensive series of articles from the laboratory of Merrifield, the amino
acids in glucagon responsible for receptor binding and signal transduction were
identified. It was established that His1, Asp9, Ser11, and Ser16 are involved in receptor
activation and Ser2, Ser8 and Asp15 are important in receptor binding [36]. In addition, it
was shown that the positively charged residues Lys12, Arg17, and Arg18 are necessary to
ensure high biological potency by stabilizing the ligand-receptor interaction [37].
Structure-activity studies of human GLP-1 have shown that the amino acids His1, Gly4,
Phe6, Thr7, and Asp9 in the N-terminal domain play an important role in binding and
activation of the GLP-1 receptor and Phe22 and Ile23 in the C-terminal domain are of
critical importance in maintaining the conformation of the molecule that is recognized
by the receptor [38]. In addition, it is known that the Ala18, Ala19, Lys20, and Leu26
residues of GLP-1 interact with N-terminal extracellular domain of the receptor and so
influence binding affinity [39]. The primary structures of the fish peptides are
13
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
compared in Fig. 8 with those of glucagon, oxyntomodulin, GLP-1, and the GLP1R
agonist, exendin-4 that was first isolated from the venom of a reptile, the Gila monster
Heloderma suspectum [40].
It is apparent that the primary structure of glucagon has been better preserved
during the course of evolution than that of GLP-1. The His1, Asp9, Ser11, and Lys12
residues of glucagon have been conserved in all fish peptides and a positively charged
residue (Arg or Lys) is present at position 17. Similarly, the His1, Gly4, Phe5, Asp9,
Phe22, and Leu26 residues of GLP-1 have also been conserved in all fish peptides tested
and all peptides contain a Val residue instead of Ile at position 23. Thus, sequence
differences at these sites are not responsible for the observed differences in activity and
specificity of the fish peptides. The high potency of paddlefish glucagon was
unexpected in view of the fact that it contains the substitutions Ser8 → Asn and Ser16 →
Glu which would be expected to reduce ability to bind to and activate GCGR and Ala18
→ Arg which would be expected to reduce binding affinity to GLP1R. However, the
peptide contains the segments Glu15-Glu16 and Glu24-Trp25-Leu26-Lys27-Asn28-Gly29 in
common with GLP1R agonist, exendin-4 that are not found in the other fish peptides
(Fig. 8).
Exendin-4 is both more potent and has a longer half-life in the circulation than
GLP-1 and is in use in clinical practice as exenatide [41]. Thus, paddlefish may be
regarded as a naturally occurring glucagon/exendin-4 hybrid peptide with dual agonist
activity at the glucagon and GLP-1 receptors. A previous study has shown that twice-
daily administration of the hybrid peptide [S2s]glucagon-exendin-4 (31-39) to high fat-
fed mice for 28 days reduced body weight, energy intake and non-fasting glucose
levels, as well as increasing insulin concentrations and improving glucose tolerance and
insulin sensitivity [42]. Glucagon/exendin-4 hybrid peptides have also been designed
14
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
that show agonist activity at GLP1R and antagonist activity at GCGR [43]. GLP-1 and
glucagon lack defined secondary structure in aqueous solution, but in membrane-
mimetic environments, adopt an α-helical structure in the midsection, with flexible N-
and C-terminal regions and it has been suggested that the helical structure is required
for binding to their respective receptors [43]. The conformations of the fish glucagons
have yet to be determined experimentally but application of the AGADIR program, an
algorithm based on the helix/coil transition theory which predicts the helical behaviour
of monomeric peptides [44] indicates that paddlefish glucagon has a very strong
propensity to adopt a stable α-helical conformation between residues 8-27 whereas the
predicted helices adopted by the dogfish, ratfish, and lamprey peptides are much less
stable. In addition, it is suggested that the relatively weak insulinotropic activity of trout
glucagon may arise from the substitutions Asp15 → Leu decreasing binding affinity at
GCGR and Thr7 → Ser and Lys20 → Gln decreasing affinity at GLP1R. In common
with most teleost fish studied to-date, the trout genome contains two genes encoding
proglucagon that are presumed to have arisen as a result of an ancient whole genome
duplication event [16]. Trout glucagon II contains five amino acid substitutions (His1 →
Gln, Asp9 →Tyr, Gln20 → Arg, Val23 → Leu and Gln24 → His) compared with the
peptide used in this study [24]. The insulinotropic and glucose-lowering activities of
this paralog have yet to be determined but, in light of the substitutions at positions 1
and 9, the peptide is unlikely to display glucagon-like biological activities in
mammalian test systems.
Structure-activity relationships of the oxyntomodulin molecule have been less
well studied than those of glucagon. The insulinotropic activities and receptor
selectivities of ratfish and dogfish oxyntomodulin differ appreciably and it is suggested
that the substitution Ser2 → Thr in the ratfish peptide contributes to its inability to
15
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
activate GCGR and the substitutions Thr7 → Ser and Ala19 → Thr are, at least in part,
responsible for its lower potency and effectiveness in stimulating GLP1R-mediated
insulin release in vitro and weaker glucose-lowering activity in vivo compared with
dogfish oxyntomodulin. Replacement of residues 15-23 in oxyntomodulin (Asp-Ser-
Arg-Arg-Ala-Gln-Asp-Phe-Val) by the corresponding section of exendin-4 (Glu-Glu-
Glu-Ala-Val-Arg-Leu-Phe-Val) resulted in an approximately 10-fold increase in
binding affinity at the rat GLP-1 receptor [45] but neither dogfish not ratfish
oxyntomodulins show structural similarity with exendin-4 in this region.
In conclusion, this study has extended earlier work that identified dogfish
glucagon as a peptide that interacts with both the GLP-1 and glucagon receptors to
stimulate insulin release and lower blood glucose concentrations [13,14] by
demonstrating that glucagon-related peptides from other phylogenetically ancient fish
possess similar properties. In particular, paddlefish glucagon, by incorporating
structural features found in exendin-4, is more potent in stimulating insulin release from
rat clonal β-cells than dogfish glucagon (threshold concentration 30 pmol L-1 versus 100
pmol L-1) and provokes a greater insulin release response than human GLP-1 when
administered to mice. In the light of the global pandemic of obesity-related T2DM,
there is an urgent need for new types of safe and more effective anti-diabetic agents.
The structure-activity properties of fish glucagon-related peptides revealed for the first
time in this study will aid in the design of new therapeutic agents. Paddlefish glucagon
in particular has the potential to act as a template for development of new long-acting,
peptidase-resistant analogues for treatment of patients with the disease that display the
advantages of unimolecular dual agonist peptides [2,3].
16
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
Acknowledgements
The work was supported by the Northern Ireland Department of Education and
Learning (DEL) and Ulster University Strategic Funding. The authors wish to thank
Bernard Thorens (University of Lausanne, Switzerland) for GLP-1 receptor-transfected
CHL cells, Cecilia Unson (The Rockefeller University, USA) for glucagon receptor-
transfected HEK293 cells, and Jaqueline Naylor (MedImmune, Cambridge, UK) for
CRISPR/Cas9-engineered INS-1 cells.
Declaration of interest
The authors declare no conflict of interest
Author Contributions
P.R.F., Y.H.A., and J.M.C. conceived and designed the study. GVG performed the in
vitro and animal experiments. GVG and JMC purified the synthetic peptides.and wrote
the manuscript. All authors analyzed and interpreted the data and have approved the
final submission.
17
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
References
1. C.J. Bailey, Glucose-lowering therapies in type 2 diabetes: Opportunities and
challenges for peptides, Peptides 100 (2018) 9-17.
2. N. Khajavi, H. Biebermann, M. Tschöp, R. DiMarchi, Treatment of diabetes and
obesity by rationally designed peptide agonists functioning at multiple metabolic
receptors, Endocr. Dev. 32 (2017) 165-182.
3. S.J. Brandt, A. Götz, M.H. Tschöp, T.D. Müller, Gut hormone polyagonists for
the treatment of type 2 diabetes, Peptides 100 (2018) 190-201.
4. A. Hasib, M.T. Ng, D. Khan, V.A.Gault, P.R.Flatt, N. Irwin N, A novel
GLP-1/xenin hybrid peptide improves glucose homeostasis, circulating lipids and
restores GIP sensitivity in high fat fed mice, Peptides 100 (2018) 202-211.
5. M.A. Sánchez-Garrido, S.J. Brandt, C. Clemmensen, T.D. Müller, R.D. DiMarchi,
M.H. Tschöp, GLP-1/glucagon receptor co-agonism for treatment of obesity,
Diabetologia 60 (2017) 1851-1861.
6. H.S. Tager, D.F. Steiner, Isolation of a glucagon-containing peptide: primary
structure of a possible fragment of proglucagon, Proc. Natl. Acad. Sci. USA 70
(1973) 2321-2325.
7. P. Blache, A. Kervran, D. Bataille, Oxyntomodulin and glicentin: brain-gut
peptides in the rat, Endocrinology 123 (1988) 2782-2787.
8. A. Pocai, Unraveling oxyntomodulin, GLP-1's enigmatic brother, J. Endocrinol.
235 (2012) 335-346.
9. J.J. Holst, N.J.W. Albrechtsen, M.B.N. Gabe, M.M. Rosenkilde, Oxyntomodulin:
actions and role in diabetes, Peptides 100 (2018) 48-53.
18
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
10. M.A. Cohen, S.M. Ellis, C.W. Le Roux, R.L. Batterham, A. Park, M. Patterson, et
al., Oxyntomodulin suppresses appetite and reduces food intake in humans, J.
Clin. Endocrinol. Metab. 88 (2003) 4696-4701.
11. V.K. Bhat, B.D. Kerr, P.R. Flatt, V.A. Gault, A novel GIP-oxyntomodulin hybrid
peptide acting through GIP, glucagon and GLP-1 receptors exhibits weight
reducing and anti-diabetic properties, Biochem. Pharmacol. 85 (2013) 1655-1662.
12. J.M. Conlon, N. Hazon, L. Thim, Primary structures of peptides derived from
proglucagon isolated from the pancreas of the elasmobranch fish, Scyliorhinus
canicula, Peptides 15 (1994) 163-167.
13. F.P.M. O’Harte, M.T. Ng, A.M. Lynch, J.M. Conlon, P.R. Flatt, Novel dual
agonist peptide analogues derived from dogfish glucagon show promising in vitro
insulin releasing actions and anti-hyperglycaemic activity in mice, Mol. Cell.
Endocrinol. 431 (2016) 133-144.
14. F.P.M. O’Harte, M.T. Ng, A.M. Lynch, J.M. Conlon, P.R. Flatt, Dogfish
glucagon analogues counter hyperglycaemia and enhance both insulin secretion
and action in diet-induced obese diabetic mice, Diabetes Obes. Metab. 18 (2016)
1013-1024.
15. G.V. Graham, J.M. Conlon, Y.H. Abdel-Wahab, V.A. Gault, P.R. Flatt,
Evaluation of the insulinotropic and glucose-lowering actions of zebrafish GIP in
mammalian systems: evidence for involvement of the GLP-1 receptor, Peptides
100 (2018) 182-189.
16. D.M. Irwin, S. Mojsov, Diversification of the functions of proglucagon and
glucagon receptor genes in fish, Gen. Comp. Endocrinol. 261 (2018) 148-165.
19
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
17. Y. Wang, P.F. Nielsen, J.H. Youson, I.C. Potter, J.M. Conlon, Multiple forms of
glucagon and somatostatin isolated from the intestine of the southern-hemisphere
lamprey Geotria australis, Gen. Comp. Endocrinol. 113 (1999) 274-82.
18. J.M. Conlon, J.H. Youson, T.P. Mommsen, Structure and biological activity of
glucagon and glucagon-like peptide from a primitive bony fish, the bowfin (Amia
calva), Biochem. J. 295 (1993) 857-861.
19. J.M. Conlon, R. Göke, P.C. Andrews, L. Thim, Multiple molecular forms of
insulin and glucagon-like peptide from the Pacific ratfish (Hydrolagus colliei),
Gen. Comp. Endocrinol. 73 (1989) 136-146.
20. K.D. Crow, C.D. Smith, J.F. Cheng, G.P. Wagner, C.T. Amemiya, An
independent genome duplication inferred from Hox paralogs in the American
paddlefish - a representative basal ray-finned fish and important comparative
reference, Genome. Biol. Evol. 4 (2012) 937-953.
21. E.M. Plisetskaya, T.P. Mommsen, Glucagon and glucagon-like peptides in
fishes, Int. Rev. Cytol. 68 (1996) 187-257.
22. J.M. Conlon, P.F. Nielsen, J.H. Youson, Primary structures of glucagon and
glucagon-like peptide isolated from the intestine of the parasitic phase lamprey
Petromyzon marinus. Gen. Comp. Endocrinol. 91 (1993) 96-104.
23. T.M. Nguyen, T.P. Mommsen, S.M. Mims, J. M. Conlon, Characterization of
insulins and proglucagon-derived peptides from a phylogenetically ancient fish,
the paddlefish (Polyodon spathula), Biochem. J. 300 (1994) 339-345.
24. D.M. Irwin, J. Wong, Trout and chicken proglucagon: alternative splicing
generates mRNA transcripts encoding glucagon-like peptide 2, Mol.
Endocrinol. 9 (1995) 267-277.
20
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
25. J.M. Conlon, R.C. Moffett, J. Leprince, P.R. Flatt, Identification of components
in frog skin secretions with therapeutic potential as antidiabetic agents, Methods
Mol. Biol. 719 (2018) 319-333.
26. N.H. McClenaghan, C.R. Barnett, E. Ah-Sing, Y.H.A.Abdel-Wahab, F.P.
O’Harte, T.W. Yoon et al., Characterization of a novel glucose-responsive
insulin-secreting cell line BRIN-BD11 produced by electrofusion, Diabetes 45
(1996) 1132-1140.
27. J.T. McCluskey, M. Hamid, H. Guo-Parke, N.H. McClenaghan, R. Gomis, P.R.
Flatt, Development and functional characterization of insulin-releasing human
pancreatic beta cell lines produced by electrofusion, J. Biol. Chem. 286 (2011)
21982-21992.
28. B.O. Owolabi, O.O. Ojo, D.K. Srinivasan, J.M. Conlon, P.R. Flatt, Y.H. Abdel-
Wahab, In vitro and in vivo insulinotropic properties of the multifunctional frog
skin peptide hymenochirin-1B: a structure-activity study, Amino Acids 48 (2016)
535-544.
29. B. Thorens, A. Porret, L. Buhler, S.P. Deng, P. Morel, C. Widmann, Cloning and
functional expression of the human islet GLP-1 receptor. Demonstration that
exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor,
Diabetes 42 (1993) 1678-1682.
30. F.P.M. O'Harte, Z.J. Franklin, E.P. Rafferty, N. Irwin, Characterisation of
structurally modified analogues of glucagon as potential glucagon receptor
antagonists, Mol. Cell. Endocrinol. 381 (2013) 26-34.
21
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
31. V. Pathak, V.A. Gault, P.R. Flatt, N. Irwin, Antagonism of gastric inhibitory
polypeptide (GIP) by palmitoylation of GIP analogues with N- and C-terminal
modifications improves obesity and metabolic control in high fat fed mice, Mol.
Cell. Endocrinol. 401 (2015) 120-129.
32. P.R. Flatt, C.J. Bailey, Development of glucose intolerance and impaired plasma
insulin response to glucose in obese hyperglycaemic (ob/ob) mice, Horm. Metab.
Res. 13 (1981) 556-560.
33. M. Goto, T. Maki, T. Kiyoizumi, S. Satomi, A.P.Monaco, An improved method
for isolation of mouse pancreatic islets, Transplantation 40 (1985) 437-438.
34. T. Ikegami, A.M. Cypess, B. Bouscarel, Modulation of glucagon receptor
expression and response in transfected human embryonic kidney cells, Am. J.
Physiol. Cell. Physiol. 281 (2001) 396–1402.
35. J. Naylor, A.T. Suckow, A. Seth, D.J. Baker, I. Sermadiras, P. Ravn, et al., Use
of CRISPR/Cas9-engineered INS-1 pancreatic β cells to define the pharmacology
of dual GIPR/GLP-1R agonists, Biochem. J. 473 (2016) 2881-2891.
36. C.G. Unson, R.B. Merrifield, Identification of an essential serine residue in
glucagon: implication for an active site triad, Proc. Natl. Acad. Sci. USA 91
(1994) 454-458.
37. C.G. Unson, C.R. Wu, C.P. Cheung, R.B. Merrifield, Positively charged residues
at positions 12, 17, and 18 of glucagon ensure maximum biological potency, J.
Biol. Chem. 273 (1998) 10308-10312.
38. B. Gallwitz, M. Witt, G. Paetzold, C. Morys-Wortmann, B. Zimmermann, K.
Eckart, et al. Structure/activity characterization of glucagon-like peptide-1, Eur.
J. Biochem. 225 (1994) 1151-1156.
22
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
39. C.R. Underwood, P. Garibay, L.B. Knudsen, S. Hastrup, G.H. Peters, R. Rudolph
R, et al., Crystal structure of glucagon-like peptide-1 in complex with the
extracellular domain of the glucagon-like peptide-1 receptor, J. Biol. Chem. 285
(2010) 723-730.
40. J. Eng, W.A. Kleinman, L. Singh, G. Singh, J.P. Raufman, Isolation and
characterization of exendin-4, an exendin-3 analogue, from Heloderma
suspectum venom. Further evidence for an exendin receptor on dispersed acini
from guinea pig pancreas, J. Biol. Chem. 267 (1992) 7402-7405.
41. F.K. Knop, A. Brønden, T. Vilsbøll, Exenatide: pharmacokinetics, clinical use,
and future directions, Expert Opin. Pharmacother. 18 (2017) 555-571.
42. A.M. Lynch, N. Pathak, V. Pathak, F.P. O'Harte, P.R. Flatt, N. Irwin et al., A
novel DPP IV-resistant C-terminally extended glucagon analogue exhibits
weight-lowering and diabetes-protective effects in high-fat-fed mice mediated
through glucagon and GLP-1 receptor activation, Diabetologia 57 (2014) 1727-
1736.
43. C.Q. Pan, J.M. Buxton, S.L. Yung, I. Tom, L. Yang, H. Chen et al., Design of a
long acting peptide functioning as both a glucagon-like peptide-1 receptor agonist
and a glucagon receptor antagonist, J. Biol. Chem. 28 (2006) 12506-12515.
44. V. Muñoz, L. Serrano, Elucidating the folding problem of helical peptides using
empirical parameters. Nat. Struct. Biol. 1 (1994) 399-409.
45. M.R. Druce, J.S. Minnion, B.C. Field, S.R. Patel, J.C. Shillito, M. Tilby M, et al.,
Investigation of structure-activity relationships of oxyntomodulin (Oxm) using
Oxm analogs, Endocrinology 150 (2009) 1712-1722.
23
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
Table 1. Primary structures and molecular masses of the glucagon-related fish
peptides used in this study
Peptide Amino acid sequence Calculated Observed molecular molecular mass (Da) mass (Da)
Lamprey glucagon HSEGTFTSDYSKYLENKQAKDFVRWLMNA 3466.9 3466.5
Dogfish oxyntomodulin HSEGTFTSDYSKYMDNRRAKDFVQWLMSTKRNG 3957.4 3958.5
Ratfish oxyntomodulin HTDGIFSSDYSKYLDNRRTKDFVQWLLSTKRNGANT 4235.6 4233.6
Paddlefish glucagon HSQGMFTNDYSKYLEEKRAKEFVEWLKNGKS 3751.1 3750.8
Trout glucagon HSEGTFSNDYSKYQLERMAQDFVQWLMNS 3512.9 3512.4
24
1
2
34567
8
9
10
11
12
13
Table 2. Effects of glucagon-related peptides on the release of insulin from BRIN-
BD11 cells.
The values are mean ± S.E.M. for n = 8. *P < 0.001 compared to 5.6 mmol L-1 glucose
control. The values are derived from the data shown in Figure 1. The threshold
concentration is the minimum concentration of the peptide producing a significant (p <
0.05) increase in the rate of insulin release. The rate of insulin release at 3 µm
concentration represent the maximum or near maximum rate.
25
Peptide Threshold concentration
Rate at 3 µM ng 106 cells-1 20 min-1
Control (glucose alone) 1.02 ± 0.02
Lamprey glucagon 3 nmol L-1 3.3 ± 0.2*
Dogfish oxyntomodulin 1 nmol L-1 2.4 ± 0.1*
Ratfish oxyntomodulin 3 nmol L-1 2.3 ± 0.2*
Paddlefish glucagon 30 pmol L-1 3.6 ± 0.2*
Trout glucagon 30 nmol L-1 1.6 ± 0.1*
Human glucagon 10 nmol L-1 2.7 ± 0.1*
Human GLP-1 10 pmol L-1 3.6 ± 0.2*
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
Legends to figures
Figure 1 Concentration-dependence of the effects of (A) lamprey glucagon, (B) dogfish
oxyntomodulin, (C) ratfish oxyntomodulin, (D) paddlefish glucagon (E) trout glucagon
(F) human glucagon and (G) human GLP-1 on the release of insulin from BRIN-BD11
rat clonal β- cells. Values are mean ± S.E.M., n = 8. *P < 0.05, **P < 0.01, ***P <
0.001 compared to 5.6 mmol L-1 glucose alone.
Figure 2 Effects of glucagon-related peptides (10-8 and 10-6 M) on insulin release from
human 1.1 B4 cells. Values are mean ± S.E.M., n = 8. *P < 0.05, *P < 0.01,
***P < 0.001 compared to 16.7 mmol L-1 glucose alone. ΔΔP < 0.01 and ΔΔΔP < 0.001
compared to GLP-1.
Figure 3 Effects of glucagon-related peptides (10 nmol L-1 and 1 µmol L-1) on insulin
release from pancreatic islets isolated from NIH Swiss mice. The values are mean ±
S.E.M. for n = 4; *P < 0.05, **P < 0.01, ***P < 0.001 compared to 16.7 mmol L-1
glucose alone. ΔP < 0.05. ΔΔP < 0.01 and ΔΔΔP < 0.001 compared to GLP-1.
Figure 4 Effects of (A) the GLP-1 receptor antagonist, exendin-4(9-39), (B) the
glucagon receptor antagonist [desHis1,Pro4,Glu9]glucagon amide and (C) the GIP
receptor antagonist GIP(6-30)Cex-K40[Pal], on the ability of glucagon-related peptides
(0.1 µmol/L) to stimulate insulin release from BRIN-BD11 cells. Values are mean ±
S.E.M., n = 8 **P < 0.01, ***P < 0.001 compared with 5.6 mmol L-1 glucose alone.
ΔΔP < 0.01, ΔΔΔP < 0.001 compared with the effect in the presence of antagonist.
26
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
Figure 5. Effects of glucagon-related peptides and GIP (10 nmol L-1 and 1 µmol L-1)
on cAMP production in (A) GLP1R-transfected CHL cells, and (B) GCGR-transfected
HEK293 cells. Values are mean ± S.E.M. for n = 4. *P < 0.05, ** P< 0.01 and ***p <
0.001 compared with 5.6 mmol L-1 glucose. In panel A, ΔP < 0.05, ΔΔΔP < 0.001
compared with the effect of GLP-1. In panel B, ΔΔP < 0.01, ΔΔΔP < 0.001 compared with
the effect of glucagon.
Figure 6. Effects of glucagon-related peptides (10 nmol L-1 and 1 µmol L-1) on the rate
of insulin release from (A) wild-type INS-1 cells, (B) CRISPR/Cas9-engineered GLP-
1R knock-out cells, and (C) CRISPR/Cas9-engineered GIPR knock-out cells. Values
are mean ± S.E.M., n = 8, *P < 0.05, **P < 0.01 and ***P < 0.001 compared with 5.6
mmol L-1 glucose alone. ΔP < 0.05, ΔΔP < 0.01, ΔΔΔP < 0.001 compared with effects in
wild-type INS-1 cells.
Figure 7. Effects of acute administration of glucagon-related peptides (25 nmol kg
body weight-1) on blood glucose (panels A and C) and plasma insulin (panels B and D)
concentrations in mice after intraperitoneal injection of glucose (18 mmol kg body
weight-1). The integrated responses are shown in panels E and F. The values are mean ±
S.E.M., n = 6. *P < 0.05, **P < 0.01 and ***P < 0.001 compared with glucose alone
and Δ P < 0.05, and ΔΔP < 0.01 compared with GLP-1.
27
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
Figure 8 A comparison of the primary structures of the glucagon-related fish peptides
with those of human glucagon, oxyntomodulin and GLP-1 and with the GLP1R
agonist, exendin-4. Amino acid residues in the human peptides that have been shown to
be important in receptor binding and signal transduction are shown in red. Differences
in these residues are shown in green. Regions of structural similarity between
paddlefish glucagon and exendin-4 are underlined. The values in parentheses show %
sequence identity with the corresponding human peptides.
28
1
2
3
4
5
6
7
8
Fig. 1
29
1
2
3
4
5
6
Fig.2
30
1
2
3
4
5
6
7
8
9
Fig. 3
31
1
2
3
4
5
6
7
8
9
10
Fig. 4
32
1
2
3
Fig. 5
33
1
2
Fig. 6
34
1
2
3
4
5
Fig. 7
35
1
2
3
4
5
67
Glucagon HSQGTFTSDY10SKYLDSRRAQ20DFVQWLMNTOxyntomodulin HSQGTFTSDY SKYLDSRRAQ DFVQWLMNTKRNKNNIA Lamprey glucagon HSEGTFTSDY SKYLENKQAK DFVRWLMNA (72)Dogfish oxyntomodulin HSEGTFTSDY SKYMDNRRAK DFVQWLMSTKRNG (83) Ratfish oxyntomodulin HTDGIFSSDY SKYLDNRRTK DFVQWLLSTKRNGANT (69) Paddlefish glucagon HSQGMFTNDY SKYLEEKRAK EFVEWLKNGKS (66)Trout glucagon HSEGTFSNDY SKYQLERMAQ DFVQWLMNS (72)
GLP-1 HAEGTFTSDV10SSYLEGQAAK20EFIAWLVKGR30G Exendin-4 HGEGTFTSDL SKQMEEEAVR LFIEWLKNGGPSSGAPPPSLamprey glucagon HSEGTFTSDY SKYLENKQAK DFVRWLMNA (57) Dogfish oxyntomodulin HSEGTFTSDY SKYMDNRRAK DFVQWLMSTKRNG (50)Ratfish oxyntomodulin HTDGIFSSDY SKYLDNRRTK DFVQWLLSTKRNGANT (40) Paddlefish glucagon HSQGMFTNDY SKYLEEKRAK EFVEWLKNGKS (57)Trout glucagon HSEGTFSNDY SKYQLERMAQ DFVQWLMNS (40)
Fig. 8
36
123456789
1011121314151617
18